

PHARMACEUTICAL 2019

ATHERSYS INC NEW Rank 233 of 371



Selling, Cost of Goods General and Research and Other Expenses Sold Administrative Development 67.5% 35.5% Expense -106% 131% 35.5% 67.5% 131% -106% Property and Assets, Intangible Other Net Expenses 128% Other Assets Revenues Equipment -11.6% Current Assets Income -43.5% 102% -87.3% -66.4% 21.2% -11.6% -87.3% -66.4% -43.5% 128% 21.2% 102% Other Compr. Assets Net Income Net Income -161% 251% -129% -114% 251% -129% Stockholders Comprehensive Equity -42.2% -85.8% Net Income 123% -42.2% 123% Economic Capital Ratio 80.1%



PHARMACEUTICAL 2019

ATHERSYS INC NEW Rank 233 of 371



The relative strengths and weaknesses of ATHERSYS INC NEW are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ATHERSYS INC NEW compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 251% points. The greatest weakness of ATHERSYS INC NEW is the variable Other Compr. Net Income, reducing the Economic Capital Ratio by 129% points.

The company's Economic Capital Ratio, given in the ranking table, is -251%, being 80% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	57,840
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,475
Liabilities, Non-Current	0
Other Assets	888
Other Compr. Net Income	-24,283
Other Expenses	855
Other Liabilities	0
Other Net Income	1,379
Property and Equipment	3,002
Research and Development	38,656
Revenues	24,291
Selling, General and Administrative Expense	10,442

Output Variable	Value in 1000 USD
Assets	61,730
Liabilities	15,475
Expenses	49,953
Stockholders Equity	46,255
Net Income	-24,283
Comprehensive Net Income	-36,424
Economic Capital Ratio	-251%